Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673344 | 0.94 | ACHE (0.51) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL4673239 | 0.92 | DRD4 (0.47) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL4674202 | 0.91 | ACHE (0.56) | DRD4BCHEACHEFAAHMCHR1 | |
| SCHEMBL4672981 | 0.90 | CCR3 (0.56) | DRD4BCHEACHEFAAHCCR3 | |
| Hydrochloric Acid SCHEMBL4680340 | 0.90 | CCR3 (0.55) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL4674864 | 0.90 | DRD4 (0.45) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL4673654 | 0.89 | ACHE (0.50) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL4675682 | 0.89 | AKR1B1 (0.55) | DRD4BCHEACHEFAAHCCR3 | |
| SCHEMBL7486233 | 0.88 | AKR1B1 (0.44) | DRD4BCHEACHEFAAH | |
| SCHEMBL4674297 | 0.88 | AKR1B1 (0.44) | DRD4BCHEACHEFAAHMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | claimed |
| US-6562825-B1 | For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies | ASTRAZENECA UK LIMITED (GB) | 2003-05-13 | — | — | US | claimed |
| EP-1196404-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca UK Limited (GB) | 2002-04-17 | — | — | EP | claimed |
| WO-2001002381-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-01-11 | — | — | WO | claimed |
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-6562825-B1 | For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies | ASTRAZENECA UK LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |